In chronic obstructive pulmonary disease (COPD), treatment with inhaled corticosteroids
(ICSs) in combination with long acting beta-2-agonists (LABA) or LABA/long-acting …

Chronic obstructive pulmonary disease (COPD) has a 3-year mortality rate up to 37%, 2–6
times higher than the general population. We present evidence supporting pharmacological …

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document for the
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Chronic obstructive pulmonary disease (COPD) is a complex condition with pathophysiology
and clinical characteristics that vary in presence and severity between patients (1). This …

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and
morbidity worldwide. In addition to generating high healthcare costs, COPD imposes a …

In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …

COPD imposes considerable worldwide burden in terms of morbidity and mortality. In
recognition of this, there is now extensive focus on early diagnosis, secondary prevention …

This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …

Chronic obstructive pulmonary disease (COPD), characterized by chronic airways
inflammation and progressive airflow limitation, is a common, preventable and treatable …